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Pulmonary diseases are potentially severe late complications of childhood cancer 42 
treatment that increase mortality risk among survivors. This nationwide study assesses 43 
the prevalence and incidence of pulmonary diseases in long-term childhood cancer 44 
survivors and their siblings, and quantifies treatment-related risks. 45 
Methods 46 
As part of the Swiss Childhood Cancer Survivor Study we studied childhood cancer 47 
survivors who were diagnosed between 1976-2005 and alive at least five years after 48 
diagnosis. We compared prevalence of self-reported pulmonary diseases (pneumonia, 49 
chest wall abnormalities, lung fibrosis, emphysema) between survivors and their 50 
siblings, calculated cumulative incidence of pulmonary diseases using the Kaplan-Meier 51 
method, and determined risk factors using multivariable logistic regression.  52 
Results 53 
Childhood cancer survivors reported more pneumonias (10% vs. 7%, P=0.020) and 54 
chest wall abnormalities (2% vs. 0.4%, P=0.003) than siblings. Treatment with busulfan 55 
was associated with prevalence of pneumonia (odds ratio [OR] 4.0, 95% confidence 56 
interval [CI] 1.1-14.9), and thoracic surgery was associated with chest wall 57 
abnormalities and lung fibrosis (OR 4.1, 95%CI 1.6-10.7 and OR 6.3, 95%CI 1.7-26.6). 58 
Cumulative incidence of any pulmonary disease after 35 years of follow-up was 21%. 59 
For pneumonia, the highest cumulative incidence was seen in childhood cancer 60 




This nationwide study in childhood cancer survivors found an increased risk for 64 
pulmonary diseases, especially pneumonia, while still young, which indicates that 65 
childhood cancer survivors need long-term pulmonary follow-up.  66 
6 
Introduction 67 
Pulmonary diseases are potentially severe late complications of childhood cancer 68 
treatments. Bleomycin, alkylating agents, radiotherapy to the thorax, and thoracic 69 
surgery can lead to restrictive lung disease.1,2 Especially when followed by chronic graft 70 
versus host disease, allogeneic hematopoietic stem cell transplantation (HSCT) can 71 
cause obstructive lung disease such as bronchiolitis obliterans or restrictive lung 72 
disease like lung fibrosis.2 Childhood cancer survivors (CCS) have a three-fold 73 
increased risk for hospitalization for pulmonary diseases and up to 14 times increased 74 
risk for late pulmonary death,3-5 with pneumonia being particularly common.6 Impaired 75 
lung function has been found in a large proportion of CCS (44–65%) depending on 76 
inclusion criteria and type of lung function tests.7-10 The US Childhood Cancer Survivor 77 
Study (CCSS) included CCS diagnosed 1970-1986 and found more lung fibrosis, 78 
recurrent pneumonia, chronic cough, and chest wall abnormalities in CCS than in their 79 
siblings.11,12 The incidence of pulmonary diseases remained elevated up to 25 years 80 
after cancer diagnosis.13 81 
Data on pulmonary diseases in CCS are nevertheless scarce. Few studies have 82 
been conducted in Europe, where treatment protocols differ from those used in the US. 83 
Previous studies have come from selected high profile clinics, included only certain 84 
types of cancer, or CCS treated many years ago (1970-1986).11-13 CCS treated with 85 
newer regimens need renewed study. 86 
We employed a nationwide, population-based, prospective cohort study to examine 87 
pulmonary disease in Swiss CCS diagnosed between 1976 and 2005. We compared 88 
the long-term prevalence of self-reported pneumonia, chest wall abnormalities, lung 89 
7 
fibrosis, and emphysema between CCS and their siblings, calculated cumulative 90 
incidence of pulmonary disease, and quantified treatment-related risks. 91 
Methods 92 
Swiss Childhood Cancer Survivor Study 93 
The Swiss Childhood Cancer Registry (SCCR) is a nationwide population-based 94 
cancer registry that includes all children and adolescents diagnosed with leukemia, 95 
lymphoma, central nervous system (CNS) tumors, malignant solid tumors, or 96 
Langerhans cell histiocytosis (LCH) before the age of 21.14 The Swiss Childhood 97 
Cancer Survivor Study (SCCSS) is a long-term follow-up cohort study of all patients 98 
registered in the SCCR who have been diagnosed since 1976 and who survived five or 99 
more years after initial diagnosis of cancer.15 For this study, we included all CCS, who 100 
were diagnosed 1976-2005 and aged ≥16 years at survey. 101 
Between 2007 and 2013 we sent questionnaires to all eligible CCS. Nonresponders 102 
received a second copy of the questionnaire 4–6 weeks after the first and, if they still did 103 
not answer, were contacted by phone. We asked CCS for consent to contact their 104 
siblings as a comparison group. If CCS agreed, we sent the same questionnaire without 105 
cancer-related questions to their siblings. Siblings who did not respond to the first 106 
questionnaire received a second copy 4–6 weeks later, but we did not contact them by 107 
phone. Details of the study design have been published elsewhere.15 108 
The Ethics Committee of the Canton of Bern granted approval to the SCCR and 109 
SCCSS (KEK-BE: 166/2014). In line with this approval, informed consent of registration 110 
8 
in the SCCR and corresponding studies, like the SCCSS, is collected at time of cancer 111 
diagnosis or later with the reply to the SCCSS survey. 112 
Outcome: pulmonary diseases 113 
The SCCSS questionnaire included a section on pulmonary health similar to US and 114 
British childhood cancer survivor studies.16,17 We asked CCS and siblings whether they 115 
had ever been diagnosed with pneumonia, chest wall abnormalities, lung fibrosis, or 116 
emphysema (Supplementary Fig. S1). We created a summary variable any pulmonary 117 
disease which combined all four pulmonary disease outcomes. To assess whether a 118 
pulmonary disease had occurred before or after cancer diagnosis we asked participants 119 
for the year of first occurrence. Pneumonia is associated with a high morbidity and 120 
mortality in patients with comorbidities,18 and CCS have a high burden of comorbidities 121 
due to cancer treatment.9 We increased sensitivity of the questions on pneumonia by 122 
asking about both single and repeated events. Previous studies have only asked about 123 
recurrent pneumonia.11,13 124 
Explanatory factors 125 
Information on cancer and cancer treatment 126 
We extracted these diagnosis- and treatment-related variables from the SCCR: age 127 
at cancer diagnosis, time since cancer diagnosis, cancer diagnosis, year of cancer 128 
diagnosis, chemotherapy, treatment protocol, radiotherapy, surgery, HSCT. We 129 
classified cancer diagnosis according to the International Classification of Childhood 130 
Cancer, third edition (ICCC-3) into twelve main groups and LCH.19 We assessed 131 
whether CCS had been treated with busulfan, nitrosoureas (carmustine [BCNU] or 132 
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lomustine [CCNU]), or bleomycin from data on treatment protocols. Radiotherapy to the 133 
thorax included radiotherapy to the total body, mantle field, thorax, lungs, mediastinum, 134 
or thoracic spine. We categorized radiotherapy to the thorax into four categories 135 
according to radiation doses based on radiotherapy treatment records: no radiotherapy 136 
to the thorax, 1-19 Gray (Gy), 20-39 Gy, and ≥40 Gy.20 We collected information on 137 
thoracic surgery (yes/no) and categorized the types of surgery (Supplementary Table 138 
S1). We assessed whether CCS had an autologous, allogeneic, or no HSCT. 139 
Information on sociodemographic and lifestyle characteristics 140 
From the SCCSS survey, we extracted information on sociodemographic data 141 
(gender, age at survey, Swiss language region, migration background) and lifestyle 142 
(body mass index [BMI], smoking status, performing sports). We calculated BMI from 143 
the survey’s self-reported height and weight data. For participants younger than 19 at 144 
survey, we calculated BMI z-scores using the Swiss references.21 BMI at survey was 145 
classified as underweight (>19yrs, <18kg/m2; ≤19yrs, <-2 z-scores), normal weight 146 
(>19yrs, ≥18 to <25kg/m2; ≤19yrs, ≥-2 to ≤1 z-score), overweight/obese (>19yrs, ≥25 147 
kg/m2; ≤19yrs, >1 z-score).22,23 We categorized smoking status as never smoker, ex-148 
smoker, and current smoker. We defined performing sports as engagement in at least 149 
moderate gym or sports activity for more than one hour per week.  150 
Statistical Analysis 151 
We compared long-term prevalence of self-reported pulmonary diseases between 152 
CCS and siblings ever in life using chi-squared tests. For better comparison between 153 
CCS and siblings, we standardized siblings for gender, age at survey, Swiss language 154 
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region, and migration background as described previously.24,25 Characteristics of 155 
siblings are shown in Supplementary Table S2.  156 
To estimate the cumulative incidence of pulmonary disease, we used the Kaplan-157 
Meier method. We assessed the first occurrence of any pulmonary disease separately 158 
and combined for each specific disease. For pneumonia, we also computed cumulative 159 
incidence curves for different cancer treatments. We used log-rank tests to test for 160 
equivalence of incidence curves. Start of follow-up time was age at cancer diagnosis for 161 
CCS, and for siblings mean age at cancer diagnosis of CCS. End of follow-up time was 162 
either the year of disease occurrence or time of survey completion if participants had no 163 
pulmonary disease. We imputed age at pulmonary disease if a participant reported a 164 
pulmonary disease but not the year of first occurrence using observed values (in CCS 165 
gender, age at survey, smoking status, age at cancer diagnosis, cancer diagnosis, 166 
radiotherapy to the thorax, and pulmotoxic chemotherapy; and in siblings, using gender, 167 
age at survey, smoking status, Supplementary text).26 Controls were censored at time 168 
of survey if they had no pulmonary disease. 169 
For CCS we quantified treatment-related risks by using uni- and multivariable logistic 170 
regressions. Explanatory factors were pulmotoxic chemotherapy (nitrosureas, busulfan, 171 
or bleomycin), radiotherapy to the thorax, thoracic surgery, and HSCT. We used 172 
likelihood ratio tests to assess whether explanatory variables were associated with 173 
pulmonary diseases. We adjusted for the following confounding factors mentioned in the 174 
literature: gender, age at diagnosis, smoking status, performing sport, and BMI at 175 
survey.27-29 176 
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We used R 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria) to 177 
calculate BMI z-scores and to impute missing values with the package missForest.26 For 178 
all other analysis, we used Stata (Version 14, Stata Corporation, Austin, Texas).  179 
Results 180 
Characteristics of study population 181 
Of 2,918 CCS and 1,280 siblings contacted and eligible for this analysis, 1,894 CCS 182 
(65%) and 731 siblings (57%) responded (Supplementary Fig. S2). Responders were 183 
more often female, between 20-29 years old at survey, from the German-speaking 184 
region of Switzerland, and younger at diagnosis than nonresponders. They also differed 185 
by cancer diagnosis and treatment (Supplementary Table S2). 186 
Fifty-three percent of CCS were male, median (interquartile range [IQR]) age at 187 
survey was 27 years (20–32) (Table 1). CCS performed less sport than siblings (60% 188 
vs. 67%, P=0.001) and were more often underweight (6% vs. 3%, P=0.004). Median 189 
(IQR) age at cancer diagnosis was 9 years (4–14); median time since diagnosis (IQR) 190 
was 18 years (13-23); common diagnoses were leukemia (32%), lymphoma (20%) and 191 
CNS tumors (14%). Eighty-two percent had been treated with chemotherapy and 8% 192 
had received pulmotoxic chemotherapy: 1% busulfan, 2% nitrosoureas, and 5% 193 
bleomycin. Fifteen percent of CCS had received radiotherapy to the thorax, the majority 194 
with doses between 20-39 Gy (8%). Four percent had had thoracic surgery, and 5% had 195 
received HSCT (3% autologous and 2% allogeneic) (Table 1, Supplementary Table 196 
S2).  197 
12 
Prevalence of pulmonary diseases in CCS and siblings 198 
Long-term prevalence of any pulmonary disease was higher in CCS than in siblings 199 
(12% vs. 7%, P=0.001) (Table 2, Supplementary Fig. S3). The difference in long-term 200 
prevalence of pneumonia ever in life was marked, 10% vs. 7% (P=0.020), and 3% of 201 
CCS compared to 1.5% of siblings had one pneumonia, and 0.8% vs. 0% had two or 202 
more pneumonias (overall, P=0.006) in the last two years (Table 2). When stratified by 203 
pulmotoxic treatment, CCS treated with no pulmotoxic treatment, pulmotoxic 204 
chemotherapy alone and both pulmotoxic chemotherapy and radiotherapy to the thorax 205 
had a higher long-term prevalence of pneumonia than siblings (10% vs. 7% P=0.048, 206 
15% P=0.042; and 14%, P=0.014, respectively) (Supplementary Table S3). Further, 207 
CCS reported more chest wall abnormalities (2% vs. 0.4%, P=0.003) than siblings. Lung 208 
fibrosis and emphysema were rare in both groups (0.8% vs. 0.3%, P=0.137; and 0.2% 209 
vs. 0.2%, P=0.763) (Table 2). When stratified by period of cancer diagnosis, CCS 210 
treated in 1976-1985 had a higher long-term prevalence of lung fibrosis (1.8%), than 211 
those treated in 1986-1995 (0.4%) and 1996-2005 (0.7%, P=0.026). Long-term 212 
revalence of all other pulmonary diseases did not differ between periods of cancer 213 
diagnosis (Table 3). 214 
Cumulative incidence of pulmonary disease after cancer diagnosis 215 
Over 35 years of follow-up, 21% (95% CI 15 – 28%) of CCS had developed at least 216 
one pulmonary disease (Fig. 1). The cumulative incidence was highest for pneumonia 217 
(18%, 95% CI 13-24%), lower for chest wall abnormalities (4%, 95% CI 2-9%) and lung 218 
fibrosis (3%, 95% CI 1-14%), and lowest for emphysema (0.2%, 95% CI 0.1-0.6%).  219 
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Cumulative incidence of pneumonia by treatment group 220 
Cumulative incidence of pneumonia in CCS within 25 years of follow-up differed by 221 
treatment group (Fig. 2): CCS without pulmotoxic treatment and those with radiotherapy 222 
to the thorax only had a similar cumulative incidence of pneumonia as siblings (Panel A, 223 
11%, 95% CI 9–14% vs. 9%, 95% CI 7–11%, P=0.074; Panel B, 12%, 95% CI 7–19% 224 
vs. 9%, 95% CI 7–11%, P=0.226). The graph suggests a trend, though it is not 225 
statistically significant, for increasing risk among those treated with radiotherapy to the 226 
thorax starting approximately 20 years after diagnosis. CCS treated with pulmotoxic 227 
chemotherapy had a higher cumulative incidence than siblings (Panel C, 18%, 95% CI 228 
9-33% vs. 9%, 95% CI 7–11%, P=0.014), starting soon after treatment. CCS treated 229 
with both pulmotoxic chemotherapy and radiotherapy to the thorax had the highest 230 
cumulative incidence (Panel D, 23%, 95% CI 13–38% vs. 9%, 95% CI 7–11%, P=0.001) 231 
differing from siblings. 232 
Risk factors for pulmonary disease 233 
CCS treated with busulfan were more likely to develop pneumonia (OR 4.0, 95% CI 234 
1.1 – 14.9). We found no significant effect of treatment with nitrosoureas and 235 
bleomycin.Thoracic surgery was associated with chest wall abnormalities (OR 4.1, 95% 236 
CI 1.6 – 10.7) and lung fibrosis (OR 6.3, 95% CI 1.7 – 26.6) (Fig. 3, Supplementary 237 
Table S4). There was also a trend for more chest wall abnormalities (OR 1.7, 95% CI 238 
0.7 – 4.3) and lung fibrosis (OR 2.0, 95% CI 0.6 – 6.3) in CCS treated with radiotherapy. 239 
HSCT was associated with any pulmonary disease (autologous, OR 1.7, 95% CI 0.8 – 240 
3.8; allogeneic, OR 1.8, 95% CI 0.8-4.0) and pneumonia (autologous, OR 1.7, 95% CI 241 
0.7 – 4.0; allogeneic: OR 1.9, 95% CI 0.8 – 4.4), but this was not statistically significant. 242 
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Of the assessed life style characteristics, only underweight was associated with lung 243 
fibrosis (OR 6.1, 95% CI 1.7 – 24.9).  244 
Results from univariable regression (unadjusted) are in Supplementary Table S5. 245 
Discussion 246 
Pulmonary diseases, particularly pneumonia and chest wall abnormalities, were 247 
increased in this nationwide, population-based comparison of childhood cancer 248 
survivors with their siblings. Busulfan was associated with pneumonia, and thoracic 249 
surgery with chest wall abnormalities and lung fibrosis. Cumulative incidence of all 250 
pulmonary diseases after cancer diagnosis continued to increase throughout life without 251 
reaching a plateau 25 years after diagnosis. Cumulative incidence of pneumonia 252 
differed by cancer treatment, with the highest incidence in those treated with both 253 
pulmotoxic chemotherapy and radiotherapy to the chest.  254 
The Childhood Cancer Survivor Study is a multicenter cohort study that also used 255 
patient-reported data and found a slightly increased cumulative incidence of pulmonary 256 
disease in CCS compared to siblings, 30% vs. 27% (P<0.001).11,13 The lower long-term 257 
prevalence in our study, 12%, is explained by our exclusion of asthma and chronic 258 
cough, which are very common in the general population (Supplementary text). The 259 
CCSS, which included patients diagnosed from 1970 to 1986 found fewer chest wall 260 
abnormalities (2.2% vs. 1.3%), and more lung fibrosis than we did (0.8% vs. 3.1%).11 261 
This might be because Swiss CCS were younger and the development of lung fibrosis 262 
can occur with a latency of up to 25 years,13 or because the Swiss cohort was treated 263 
with treatment protocols of more recent years, including lower radiation doses and 264 
volumes, as for example in CCS of Hodgkins Lymphoma.30 These assumptions are 265 
15 
supported by the observed lower long-term prevalence of lung fibrosis diagnosed in 266 
Swiss CCS in recent years. The proportion of CCS in our study who had repeated 267 
pneumonia within the previous two years is comparable to that in the CCSS.11 Because 268 
pneumonia is associated with high morbidity and mortality in patients with 269 
comorbidities,18 we also looked at all events of pneumonia and found that 10% of CCS 270 
had had pneumonia at some time, while the long-term prevalence was 7% in their 271 
siblings. The prevalence of pneumonia did not decrease in CCS diagnosed in recent 272 
years. The cumulative incidence of pneumonia increased over the 25-year follow-up 273 
without plateauing. Dietz et al. reported the same for recurrent pneumonia.13 The CCSS 274 
identified different risk factors for pneumonia, radiotherapy to the thorax, and HSCT,11,13 275 
while in our study pneumonia risk was higher after busulfan treatment. We also 276 
observed that cumulative incidence of pneumonia differed by treatment groups and was 277 
highest in those treated with both pulmotoxic chemotherapy and radiotherapy to the 278 
thorax. HSCT with subsequent graft versus host disease and immunodeficiency could 279 
explain development of repeated infections such as pneumonia.6,31 However, our 280 
multivariable analysis found no evidence that the association between pneumonia and 281 
busulfan was mediated via HSCT (the effect of busulfan was not reduced when we 282 
adjusted for HSCT). We found also no evidence for an independent effect of HSCT on 283 
risk of pneumonia. Therefore our results suggest that busulfan itself has a long-term 284 
effect on the immune system or lung tissues. We don’t know the underlying 285 
mechanisms, as the few experimental data from animal models and cell culture studies 286 
have focused on short-term effects. The risk for chest wall abnormalities and lung 287 
fibrosis was higher in CCS treated with radiotherapy to the thorax and thoracic surgery, 288 
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which also is similar to CCSS findings.11-13 We found a higher proportion of pulmonary 289 
disease in CCS treated with alkylating agents (busulfan) or surgery to the lungs as was 290 
also reported by Record et al.7 Lung fibrosis was associated with underweight at survey. 291 
We think this might be a secondary effect, because CCS with lung fibrosis are more 292 
likely to be sick and thus more often suffer from malnutrition and have elevated exertion 293 
because of difficulties with breathing, as hypothesized in adult idiopathic lung fibrosis 294 
patients.32 Finally, up to 65% of CCS have been found to have impaired lung-function.7-295 
10 This rate is higher than the cumulative, overall incidence of disease in our study 296 
because lung function tests may indicate subclinical pathology possibly well in advance 297 
of diagnosis of disease. 298 
Strengths of our study are the population-based nature and the high response rate 299 
that make our study population representative for the entire population of Swiss CCS. 300 
Nonresponse bias seems to play a minor role in the SCCSS. We recently assessed the 301 
difference in typical prevalence estimates (somatic health, medical care, mental health, 302 
health behaviours) among early responders (40%), all responders (69%) and a 303 
complete representative population constructed with inverse probability weighting 304 
(100%).33 We found similar results among those populations, suggesting that 305 
prevalence estimates in participants are close to the true prevalence in the total 306 
population.33 Further, we have no evidence that CCS reported differently than their 307 
siblings: asthma and chronic cough, common disorders not specifically caused by 308 
cancer treatment,34 were reported equally often (Supplementary text). Our study 309 
covers all cancer diagnoses and treatment periods from 1976 to 2005, while previous 310 
studies often focused only on specific diagnostic groups12,35 and CCS diagnosed until 311 
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1986.11,13 Last, the SCCSS assessed a large number of sociodemographic and life-style 312 
characteristics, which we could include in the analyses.  313 
The limited sensitivity and specificity of self-reported disease could have biased our 314 
results. However, one study’s comparison of self-reports of pulmonary diseases 315 
including pneumonia, lung fibrosis, and emphysema to information from medical records 316 
of childhood cancer survivors of HSCT has shown good validity (96% sensitivity, 91% 317 
specificity).36 We could not determine if the effects of drugs or radiotherapy to the thorax 318 
were dose-dependent, as we did not have exact cumulative doses of chemotherapeutic 319 
drugs and numbers of patients with pulmonary outcomes were too low to stratify them 320 
into more categories. Due to survival bias, our results might underestimate the true 321 
prevalence. The absolute numbers of CCS with pulmonary disease was small, because 322 
our study population was young, and incidence of pulmonary disease increases over 323 
the life of CCS.5,13  324 
Childhood cancer survivors are at increased risk of pneumonia, which is the most 325 
common pulmonary cause of death among CCS.6 The underlying causes of this are 326 
poorly understood. The long-term prevalence of pneumonia remained increased among 327 
CCS diagnosed in recent years and treated with newer treatment protocols. Future 328 
research should investigate pathophysiological mechanisms leading to pneumonia in 329 
CCS. Lung fibrosis and emphysema are rare; to evaluate associations with cancer-330 
treatment, international data must be pooled. The increased incidence of pulmonary 331 
disease, particularly pneumonia, continues throughout the life of a CCS, and the risk 332 
depends on the type of cancer treatment. We therefore must consider preventive 333 
measures for pneumonia such as vaccination for influenza or pneumococcal pneumonia 334 
18 
in susceptible CCS. Lifelong clinical monitoring of pulmonary health of former childhood 335 
cancer patients at risk for pulmonary disease is necessary.  336 
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disease, only the first occurrence was counted. 477 
FIGURE 2 Cumulative incidence of self-reported pneumonia in years of follow-up 478 
in survivors by treatment group and siblings  479 
Start of follow-up time was individual age at cancer diagnosis for survivors and for 480 
siblings we used mean age at cancer diagnosis of survivors. 481 
CT, Chemotherapy; RT, Radiotherapy  482 
FIGURE 3 Associations between cancer treatments and self-reported pulmonary 483 
diseases occurring after cancer diagnosis. 484 
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Multivariable logistic regression adjusted for all treatment factors shown and 485 
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 Siblings     
N = 1,894  N = 731   
 
n (%) a  n (%) a P b 






Female 898 (47)  428 (59) 
 
Male 996 (53)  303 (41) 
 





16-19 419 (22)  116 (16) 
 
20-29 892 (47)  333 (45) 
 
≥30 583 (31)  282 (39) 
 






Never smoker 1,218 (64)  457 (62) 
 
Ex-smoker 222 (12)  108 (15) 
 







No 757 (40)  242 (33) 
 
Yes 1,137 (60)  489 (67) 
 





Underweight  108 (6)  19 (3) 
 
Healthy  1,271 (67)  513 (70) 
 
Overweight/obese 515 (27)  199 (27) 
 
Clinical characteristics       
Age at diagnosis (years) 
  
 
   
0-5 695 (37)  
   
>5-10  446 (23)  
   
>10  753 (40)  
   
Period of cancer diagnosis 
  
 
   
1976 - 1985 463 (24)  
   
1986 - 1995 839 (44)  
   
1996 - 2005 592 (31)  




   
I Leukemia 601 (32)  
   
II Lymphoma 391 (20)  
   
III CNS tumor 262 (14) 
    
IV Neuroblastoma 73 (4) 
    
V Retinoblastoma 39 (2) 
    
VI Renal tumor 107 (6) 
    
VII Hepatic tumor 11 (1) 
    
VIII Bone tumor 86 (4) 
    
IX Soft tissue sarcoma 116 (6) 
    
X Germ cell tumor 94 (5) 
    
XI & XII Other rare tumors c 114 (6) 
    
 
 




      
No chemotherapy  347 (18) 
    
Any chemotherapy 1,547 (82) 
    
Pulmotoxic chemotherapy 
      
Busulfan 13 (1) 
    
Nitrosureas (BCNU/CCNU) 30 (2) 
    
Bleomycin 102 (5) 
    
Radiotherapy d 
      
No radiotherapy 1,155 (63) 
    
Any radiotherapy 739 (37) 
    
Radiotherapy to the thorax 284 (15) 
    
Dose 0-19 Gy 82 (4) 
    
Dose 20-39 Gy 143 (8) 
    
Dose >=40 Gy 50 (3) 
    
Dose unknown 9 (0.5) 
    
Surgery e 
      
No surgery 836 (44) 
    
Any surgery 1,058 (56) 
    
Thoracic surgery 80 (4) 
    
Hematopoietic stem cell transplantation (HSCT) 
     
No HSCT 1,802 (95) 
    
Any HSCT 93 (5) 
    
Autologous 48 (3) 
    
Allogenic 45 (2) 
    
 
a Column percentages are given. 
b P-values calculated from chi-squared tests comparing survivors and siblings.  
c Including Langerhans cell histiocytosis; other malignant epithelial neoplasms, 
malignant melanomas, and other or unspecified malignant neoplasms. 
d Including radiotherapy to the total body, mantle-field, thorax, lungs, mediastinum or 
thoracic spine. 
e Including thoracotomy, sternotomy, chest wall surgery, rib resection, thoracoscopy. 
 
TABLE 2 Long-term prevalence of self-reported pulmonary diseases and number of 

















 n n %  (95%CI)  n  (%)  % (95%CI)  P d 
Any pulmonary disease e 1,668 226 11.9 (10.5 - 13.5) 215 (11.4)  7. 3 (5.6 - 9.5) 0.001 
Chest wall abnormalities 1,852 42 2.2 (1.6 - 3.0) 38 (2.0)  0.4 (0.1 - 1.4) 0.003 
Lung fibrosis 1,878 16 0.8 (0.5 - 1.4) 15 (0.7)  0.3 (0.1 - 1.2) 0.137 
Emphysema 2,183 3 0.2 (0.1 - 0.5) 3 (0.1)  0.2 (0.0 - 0.9) 0.763 
Pneumonia 1,704 190 10.0 (8.8 - 11.5) 182 (9.6)  7.0 (5.3 - 9.2) 0.020 








  n % f     % f  P g 
0  82 4.3     3.5  0.006 
1  56 3.0     1.5   
>= 2  15 0.8     0   
missing  37 1.9     2.0   
 
a Siblings are weighted for gender, age at survey, Swiss language region, and migration 
background according to survivors. 
b Long-term prevalence of pulmonary diseases of survivors is calculated for survivors 
who stated “Yes, ever in life”. 
c “Yes, after diagnosis” column contains persons who affirmed having developed the 
condition after cancer diagnosis. 
d P-values calculated from chi-squared tests comparing long-term prevalence of 
survivors reporting pulmonary disease “Yes, ever in life” and long-term prevalence of 
pulmonary disease in siblings. 
e All pulmonary diseases, e.g., pneumonia, chest wall abnormalities, lung fibrosis and/or 
emphysema. 
f Column percentages are given. 
g P-values calculated from chi-squared tests comparing numbers of pneumonias in 
survivors and siblings. 
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Pneumonia Chest wall 
abnormalities 
Lung fibrosis Emphysema 










 n  n %a P b n %a P b n %a P b n %a P b n %a P b 



























1996-2005 592 63 10   52 9   12 2  4 0.7   1 0.2   
a Row percentages are given. 







Supplementary text  
Additional Methods 
Reporting of pulmonary diseases in the SCCSS 
We also looked at asthma and chronic cough in survivors and their siblings. Both are 
common in the general population. Asthma was reported by 208 (11%) of 1894 
survivors and 76 (10%) of 731 siblings, and chronic cough lasting more than 3 months 
by 78 (4%) of 1894 survivors and 29 (4%) of 731 siblings. The prevalence of asthma 
and chronic cough did not differ between survivors and siblings (P=0.979), regardless of 
whether siblings' figures were weighted for survivor’s sociodemographic characteristics 
(gender, age at survey, Swiss language region, and migration background) or not. This 
suggests that survivors did not over-report pulmonary diseases in the SCCSS 
questionnaire compared to their siblings. 
Handling of missing data 
Few participants had missing outcome data: pneumonia (66 survivors [3%], 13 siblings 
[2%]), chest wall abnormalities (51 survivors [3%], 8 siblings [1%]), lung fibrosis (55 
survivors [3%], 10 siblings [1%]), emphysema (55 survivors [3%], 12 siblings [2%]). The 
date of first occurrence of pulmonary diseases was missing in some CCS: pneumonia 
(68 of 190 survivors [36%], 16 of 58 siblings [28%]), chest wall abnormalities (12 of 42 
survivor [29%]), lung fibrosis (0 of 16 survivors [0%]), emphysema (0 of 3 survivors 
[0%]). We performed non-parametric missing value imputation for mixed type data 
(continuous and categorical) to obtain estimates for these dates using the missForest 
package in R.26  
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TABLE S1 Surgical details for survivors who had thoracic surgery 
 
  Survivors with thoracic surgery a 
 n = 80 
  n (%) b 
   
Thoracotomy 57 (71) 
Tumor biopsy 12 (15) 
Tumor resection 39 (49) 
with no further specification 23 (29) 
for pulmonary metastasectomy 8 (10) 
for pulmonary wedge resection 2 (3) 
for pulmonary lobectomy 6 (7) 
Further specification 6 (7) 
 
  
Chest wall surgery c 11 (14) 
Rib resection 7 (9) 
   
Thoracoscopy 5 (6) 
Tumor biopsy 1 (1) 
Tumor resection 4 (5) 
with no further specification 1 (1) 
for pulmonary metastasectomy 1 (1) 
for pulmonary wedge resection 2 (2) 
      
 
a Survivors were only classified to a single category. If multiple surgeries were performed, we classified 
survivors by the most severe intervention in the following sequence (severe to less severe): lobectomy > 
wedge resection > metastasectomy > no further specification > biopsy. 
b Column percentages are given.  
c Including surgery to clavicle, scapulae and ribs, tumor excision from soft tissue on thorax, muscles on 




TABLE S2 Characteristics of responding and nonresponding survivors and siblings before and after  









 Responders  Nonresponders  Unweighted  Weighted 
 N = 1,894  N = 1,024    N = 731      
 n (%)a 
 
n (%)a P b  n (%)a P b  (%)c P b 
Sociodemographic characteristics                       
 
     
  
  
    
Gender 






Female 898 (47) 
 
389 (38)   428 (59)   (48) 
 
Male 996 (53) 
 
635 (62)   303 (41)   (52) 
 
 







Age at survey (years) 






16-19 419 (22) 
 
250 (25)   116 (16)   (22) 
 
20-29 892 (47) 
 
403 (39)   333 (45)   (47) 
 
≥30 583 (31) 
 
371 (36)   282 (39)   (31) 
 
 







Swiss language region 






German  1,320 (70) 
 
655 (64)   592 (81)   (70) 
 
French 515 (27) 
 
350 (34)   117 (16)   (27) 
 
Italian 59 (3) 
 
19 (2)   22 (3)   (3) 
 
 














No 1,436 (76) 
   
  618 (85)   (76) 
 
Yes 458 (24) 
   








   
Lifestyle characteristics                           
 




   
Smoking status 
     
  
  
0.104   0.666 
Never smoker 1,218 (64) 
   
  457 (62)   (63)  
Ex-smoker 222 (12) 
   
  108 (15)   (13)  
Current smoker 454 (24) 
   




     
  
  
0.001   0.003 
No 757 (40) 
   
  242 (33)   (33)  
Yes 1,137 (60) 
   
  489 (67)   (67)  
 




   
BMI at survey 
     
  
  
0.004   0.003 
Underweight  108 (6) 
   
  19 (3)   (2)  
Healthy  1,271 (67) 
   
  513 (70)   (72)  
Overweight / Obese 515 (27) 
   
  199 (27)   (26)  
 
  
   
  
  
   
 
Clinical characteristics                           
        
  
    
Age at diagnosis (years)    <0.001        
0-5 695 (37)  300 (29)         
>5-10  446 (23)  199 (20)         
>10  753 (40)  525 (51)         
        
      
Period of cancer diagnosis     <0.001        
before 1986 463 (24)  207 (20) 
 
       
1986-1995 839 (44)  393 (38) 
 
       
after 1995 592 (31)  424 (42) 
 
       
       
 
      
Diagnosis (ICCC-3)    
  <0.001        
I Leukemia 601 (32)  223 (22)         
II Lymphoma 391 (20)  241 (24)         
III CNS tumor 262 (14)  179 (17)         
IV Neuroblastoma 73 (4)  28 (3)         
V Retinoblastoma 39 (2)  18 (2)         
VI Renal tumor 107 (6)  27 (3)         
VII Hepatic tumor 11 (1)  3 (0.3)         
VIII Bone tumor 86 (4)  57 (5)         
IX Soft tissue sarcoma 116 (6)  68 (6)         
X Germ cell tumor 94 (5)  99 (10)         
XI&XII Other rare tumors d 114 (6)  81 (8)         
    
   
 




Treatments              
Chemotherapy      <0.001        
No chemotherapy  347 (18)  361 (35)         
Any chemotherapy 1,547 (82)  663 (65)         
        
      
Radiotherapy      0.027        
No radiotherapy 1,155 (63)  667 (65)         
Any radiotherapy 739 (37)  357 (35)         
        
      
Surgery      <0.001        
No surgery 836 (44)  300 (29)         
Any surgery 1,058 (56)  724 (71)         
        
      
Hematopoietic stem cell transplantation (HSCT)  0.321        
No HSCT 1,802 (95)  983 (96)         
Any HSCT 93 (5)  41 (4)         
                            
 
a Column percentages are given.  
b P-values calculated from chi-squared tests comparing respective group to responders. 
c Column percentages given are weighted for gender, age at survey, Swiss language region, and migration background of survivors. 










Prevalence of Pneumonia a 
   %  (95%CI)  P b 
Siblings (n=731) 
 
7.0 (5.3 - 9.2)  
Survivors not treated with pulmotoxic chemotherapy 
or radiotherapy to the thorax (n=1,545) 
 
9.6 (8.2 - 11.1) 0.048 
Survivors treated with pulmotoxic chemotherapy 
(n=65) 
 
14.5 (7.3 – 27.0) 0.042 
Survivors treated with radiotherapy to the thorax 
(n=193) 
 
10.4 (6.7 - 15.5) 0.129 
Survivors treated with pulmotoxic chemotherapy and 
radiotherapy to the thorax (n=91) 
 
14.4 (8.4 - 23.5) 0.014 
 
a Prevalence of siblings is weighted for gender, age at survey, Swiss language region, and migration 
background of survivors. Prevalence of survivors is calculated with variable “Yes, ever in life.” 
b P-values calculated from chi-squared tests comparing prevalence of survivors reporting pulmonary 




TABLE S4 Associations between sociodemographic and treatment characteristics and self-reported pulmonary diseases. 




  Pneumonia     Chest wall 
abnormalities 
  Lung fibrosis 
  
 (n=215)    (n=182)    (n=38)    (n=15)   
Total N=1'894 OR (95% CI) P a   OR (95% CI) P a   OR (95% CI) P a   OR (95% CI) P a 
Socio-demographic characteristics                       
Gender   0.164    0.023    0.120    0.933 
Female Ref.    Ref.    Ref.    Ref.   
Male 0.8 (0.6 - 1.1)   0.7 (0.5 – 1.0)   1.7 (0.9 - 3.5)   1.0 (0.3 - 3.2)  
                
Age at diagnosis   0.883    0.963    0.150    0.046 
0-5 years Ref.    Ref.    Ref.    Ref.   
>5-10 years 0.9 (0.6 - 1.4)   1.1 (0.7 - 1.6)   0.4 (0.1 - 1.2)   6.3 (0.7 - 59.6)  
>10 years 1.0 (0.7 - 1.5)   1.0 (0.7 - 1.5)   0.9 (0.4 - 1.9)   8.0 (1.0 - 65.8)  
                
Lifestyle characteristics                         
Smoking status   0.214    0.816    0.409    0.107 
Never smoked Ref.    Ref.    Ref.    Ref.   
Ex-smoker 1.4 (1.0 - 2.2)   1.2 (0.7 - 1.9)   1.8 (0.7 - 4.7)   3.3 (1.0 - 10.9)  
Current smoker 1.0 (0.7 - 1.5)   1.0 (0.7 - 1.5)   1.4 (0.7 - 3.0)   0.7 (0.1 - 3.3)  
                
Performing sports   0.724    0.214    0.104    0.499 
No Ref.    Ref.    Ref.    Ref.   
Yes 1.1 (0.8 - 1.4)   1.2 (0.6 – 2.1)   0.6 (0.3 - 1.1)   0.7 (0.2 - 2.0)  
                
BMI at survey   0.697    0.717    0.289    0.037 
Underweight  1.3 (0.7 - 2.3)   1.1 (0.6 - 2.1)   1.9 (0.6 - 5.9)   6.6 (1.7 - 24.9)  
Healthy  Ref.    Ref.    Ref.    Ref.   




Therapy                               
Chemotherapy                
No pulmotoxic drug Ref.  0.405  Ref.  0.202  Ref.  0.813  n.a.b   
BCNU/CCNU 1.2 (0.4 - 3.5)   1.0 (0.3 - 3.6)   2.0 (0.2 - 16.2)      
Busulfan 2.8 (0.8 - 9.9)   4.0 (1.1 – 14.9)   1.6 (0.1 – 19.2)      
Bleomycin 1.3 (0.7 - 2.4)   1.3 (0.7 – 2.6)   0.6 (0.1 – 3.0)      
                
Radiotherapy to the thorax 0.266    0.637    0.234    0.266 
No RT to the thorax Ref.    Ref.    Ref.    Ref.   
RT to the thorax 1.3 (0.8 - 1.9)   1.1 (0.7- 1.8)   1.7 (0.7 - 4.3)   2.0 (0.6 - 6.3)  
                
Surgery   0.799    0.400    0.009    0.015 
No thoracic surgery Ref.    Ref.    Ref.    Ref.   
Thoracic surgery 1.1 (0.6 - 2.2)   0.7 (0.3 - 1.6)   4.1 (1.6 - 10.7)   6.3 (1.7 - 26.6)  
                
Hematopoetic stem cell tansplantation 0.204    0.255    0.837  n.a.b   
No HSCT Ref.    Ref.    Ref.       
Autologous 1.7 (0.8 - 3.8)   1.7 (0.7 - 4.0)   0.8 (0.1 - 7.4)      
Allogeneic 1.8 (0.8 - 4.0)   1.9 (0.8 - 4.4)   1.5 (0.3 - 6.3)      
                                
 
n.a.: Not applicable; Ref.: Reference; RT: Radiotherapy 
a P-value was calculated with likelihood ratio-tests. 





TABLE S5 Associations between sociodemographic and treatment characteristics and self-reported pulmonary diseases. Results from 
univariable logistic regression. 
 








   
(n=15) 
   
(n=3)  
      P c 
 
      P c 
 
      P c 
 
      P c 
 
    
Total N=1'894 na (%)b OR (95% CI)   n
a  (%)b OR (95% CI)   n
a (%)b OR (95% CI)   na (%)b OR (95% CI)   na  (%)b 
Socio-demographic characteristics                                      
Gender 
   
0.109 
    
0.022 
    
0.184 
    
0.645 
   
Female 113 (13) Ref. 
  
101 (11) Ref. 
  
14 (2) Ref. 
  
8 (1) Ref. 
  
3 (0.3) 
Male 102 (10) 0.8 (0.6 - 1.1) 
 
81 (8) 0.7 (0.5 - 0.9) 
 
24 (2) 1.6 (0.8 - 3.0) 
 




                      
Age at diagnosis 
   
0.536 
    
0.802 
    
0.114 
    
0.019 
   
0-5 years 75 (11) Ref. 
  
63 (9) Ref. 
  
16 (2) Ref. 
  
1 (0.1) Ref. 
  
0 (0) 
>5-10 years 47 (11) 0.7 (0.7-1.4) 
 
43 (10) 1.1 (0.7 - 1.6) 
 
4 (1) 0.4 (0.1 - 1.2) 
 
4 (1) 6.3 (0.7 - 56.4) 
 
0 (0) 
>10 years 93 (12) 1.0 (0.8-1.6) 
 
76 (10) 1.1 (0.8 - 1.6) 
 
18 (2) 1.0 (0.5 - 2.1) 
 




                      
Lifestyle characteristics                                       
Smoking status 
   
0.237 
    
0.805 
    
0.500 
    
0.076 
   
Never smoked 133 (11) Ref. 
  
116 (10) Ref. 
  
21 (2) Ref. 
  
8 (1) Ref. 
  
1 (0.1) 
Ex-smoker 33 (15) 1.5 (0.9 - 2.1) 
 
24 (11) 1.2 (0.7 - 1.8) 
 
6 (3) 1.6 (0.6 - 4.0) 
 
5 (2) 3.5 (1.1 - 10.8) 
 
0 (0) 
Current smoker 49 (11) 1.0 (0.7 - 1.4) 
 
42 (9) 1.0 (0.7 - 1.4) 
 
11 (2) 1.4 (0.7 - 3.0) 
 




                      
Performing sports 
   
0.89 
    
0.359 
    
0.055 
    
0.991 
   
No 85 (11) 
   
67 (9) Ref. 
  
21 (3) Ref. 
  
7 (1) Ref. 
  
2 (0.3) 
Yes 130 (11) 1.0 (0.8 - 1.4) 
 
115 (10) 1.2 (0.8 - 1.6) 
 
17 (2) 0.5 (0.3 - 1.0) 
 




                      
BMI at survey 
   
0.517 
    
0.815 
    
0.394 
    
0.031 
   
Underweight  16 (15) 1.4 (0.8 - 2.4) 
 
12 (9) 1.2 (0.6 - 2.3) 
 
4 (2) 1.8 (0.6 - 5.4) 
 
8 (1) 6.1 (1.8 - 20.5) 
 
2 (2) 
Healthy  143 (11) Ref. 
  
119 (11) Ref. 
  
26 (4) Ref. 
  
4 (4) Ref. 
  
1 (0.1) 
Overweight/Obese 56 (11) 1.0 (0.7 - 1.3) 
 
51 (10) 1.1 (0.8 - 1.5) 
 
8 (2) 0.8 (0.3 - 1.7) 
 





    




Therapy                                             
Chemotherapy    0.035     0.028     0.679         
No pulmotoxic 
drug 
190 (11) Ref.   161 (9) Ref.   34 (2) Ref.   12 (1)    2 (0.1) 
BCNU/CCNU 4 (13) 1.3 (0.4 - 3.7)  3 (10) 1.1 (0.3 - 3.7)  1 (3) 1.7 (0.2 - 13.1)  0 (0)    0 (0) 
Busulfan 
5 (38) 5.1 (1.7 - 
15.8) 
 5 (38) 6.2 (2.0 – 
19.1) 
 1 (8) 4.2 (0.5 – 33.2)  1 (8)    1 (8) 
Bleomycin 16 (16) 1.5 (0.9 - 2.7)  13 (13) 1.4 (0.8 - 2.6)  2 (2) 1.0 (0.2 - 4.3)  2 (2)    0 (0) 
                       
Radiotherapy to 
the thorax 
   0.035     0.028     0.679         
No RT to the 
thorax 
172 (11) Ref.   149 (9) Ref.   28 (2) Ref.   9 (0.6) Ref.   2 (0.1) 
RT to the thorax 43 (15) 1.5 (1.0 - 2.1)  33 (12) 1.3 (0.9 - 1.9)  10 (4) 2.1 (1.0 - 4.3)  6 (2) 3.8 (1.4 - 10.9)  1 (0.4) 
                       
Surgery    0.320     0.787     0.001     0.003    
No thoracic 
surgery 
203 (11) Ref.   175 (10) Ref.   31 (2) Ref.   11 (1) Ref.   1 (0.1) 
Thoracic surgery 12 (15) 1.4 (0.7 - 2.6)  7 (9) 0.9 (0.4 - 2.0)  7 (9) 5.5 (2.4 - 12.9)  4 (5) 8.6 (2.7 - 27.7)  2 (3) 
                       
Hematopoetic stem 
cell tansplantation 
   0.015     0.027     0.197         
No HSCT 195 (11) Ref.   165 (9) Ref.   34 (2) Ref.   14 (1)    2 (0.1) 
Autologus 10 (21) 2.2 (1.1 - 4.5)  9 (19) 2.3 (1.1 - 4.9)  1 (2) 1.1 (0.2 - 8.4)  0 (0)    0 (0) 
Allogeneic 10 (22) 2.4 (1.1 - 4.8)   8 (18) 2.1 (1.0 - 4.7)   3 (7) 3.7 (1.1 - 12.6)   1 (2)       1 -2 
                       
 
n.a.: Not applicable; Ref.: Reference group; RT: Radiotherapy 
a Absolute numbers of survivors reporting pulmonary outcome. 
b Row percentage are given. 
c Global P-value was calculated with likelihood ratio-tests. 






FIGURE S1 English translation of original questions for adults on pulmonary health in 
the SCCSS questionnaire 
 















FIGURE S2 Response rates in the Swiss Childhood Cancer Survivor Study for both, 
childhood cancer survivors and siblings, ≥16 years old at survey 
 
a Eligible: registered in SCCR, diagnosed 1976-2005, aged ≤20 years at diagnosis, survived for ≥5 years 
from initial cancer diagnosis and were aged ≥16 years at survey 
b Not contacted because of different reasons: sibling refused through survivor/parent; survivor does not 




N=2,708 Siblings eligible for the study 
N=1,280 (100 %) Siblings contacted 
N=539 (42 %) did not reply 
N=10 (1 %) refused 
N=731 (57 %) Siblings responded  
N=3,362 Survivors eligible for the study a 
N=2,918 (100 %) Survivors contacted 
N=837 (29 %) did not reply 
N=187 (6 %) refused  
N=1,894 (65 %) Survivors responded 
N=435 had no valid address 
N=9 had died 
N=1’269 had no valid address 
N=151 were not contacted b 






FIGURE S3 Long-term prevalence of self-reported pulmonary diseases in childhood 
cancer survivors and siblings 
 
NCCS: Number in survivors; NSIB: number in siblings 
Prevalence of siblings is weighted for gender, age at survey Swiss language region and migration 
background of survivors; Numbers are absolute values. 
